secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001193125-21-349022
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm director Mikael Dolsten resigns; Peter Honig elected to board
------------------------------------------------------------------------

- Director Mikael Dolsten resigned effective Dec 2, 2021, citing competing professional demands, no disagreement.
- Peter Honig elected independent director effective Dec 3, 2021, filling a vacancy, Class III term until 2022 annual meeting.
- Honig appointed to Commercialization and Portfolio Committee; awarded option for 47,800 shares at $6.72, vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/d203828d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-349022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer